

University of California, San Francisco
CURRICULUM VITAE

Name: Jeffry Peter Simko, MD, PhD

Position: Professor of Clinical Pathology
Pathology
School of Medicine

Address: Box 1785
1825 4th Street, M-2360
University of California, San Francisco at Mission Bay
San Francisco, CA 94143-4066
Voice: 415-353-7581
Fax: 415-353-1612
Email: jeff.simko@ucsf.edu
Web: <http://www.ucsf.edu/pathol/people/simko.htm>

EDUCATION

1981 - 1985	University of Delaware, Newark, DE	B.S.	Chemistry
1985 - 1990	University of North Carolina, Chapel Hill, NC	Ph.D.	Analytical Chemistry
1992 - 1996	University of North Carolina, Chapel Hill, NC	M.D.	Medicine
1996 - 2000	University of California, San Francisco, CA	Resident	Pathology
2000 - 2001	Harvard Medical School, Boston, MA	Fellow	Molecular Pathology
2001 - 2002	University of California, San Francisco, CA	Fellow	Surgical Pathology

LICENSES, CERTIFICATION

1998	Medical License (#A064515), Medical Board of California, Sacramento, CA
2000	Board Certification, Anatomic & Clinical Pathology (#00-309), Am. Board of Pathology
2003	Board Certification, Molecular Genetic Pathology (#1921), American Board of Pathology

PRINCIPAL POSITIONS HELD

1983 - 1985	Student Employee,	Pioneering Research Lab,	E.I. du Pont Inc., Wilmington, DE
-------------	-------------------	-----------------------------	---

1988 - 1990	Visiting Engineer,	IBM T.J. Watson Research Center, Yorktown Heights, NY	
1991 - 1992	Research Associate ,	Frontier Research Pro.,	Institute of Physical and Chemical Research (RIKEN), Wakou-shi, Saitama, Japan
2002 - 2003	Assistant Clinical Professor,	Department of Anatomic Pathology,	UC San Francisco
2003 - 2007	Assistant Professor of Pathology,	Department of Anatomic Pathology,	UC San Francisco
2003 - 2007	Assistant Professor of Pathology,	Department of Urology,	UC San Francisco
-			
2007 - 2013	Associate Professor of Pathology,	Department of Anatomic Pathology,	UC San Francisco
2007 - 2013	Associate Professor of Pathology,	Department of Urology,	UC San Francisco
2011 - 2013	Associate Professor of Pathology,	Department of Radiation Oncology	UC San Francisco
2013 – present	Professor of Pathology,	Department of Anatomic Pathology	UC San Francisco
2013 - present	Professor of Pathology,	Department of Urology	UC San Francisco
2013 - present	Professor of Pathology,	Department of Radiation Oncology	UC San Francisco

OTHER POSITIONS HELD CONCURRENTLY

2000 - 2001	Clinical Fellow,	Molecular Pathology,	Brigham and Womens' Hospital, Boston, MA
2001 - 2002	Clinical Fellow,	Surgical Pathology,	UCSF Hospitals, San Francisco, CA
2000 - 2003	Consultant,	Anatomic Pathology,	Chiron Corporation, Emeryville, CA
2002 - 2003	Consultant,	Anatomic Pathology,	Incyte Genomics Corporation, Palo Alto, CA
2002 - present	Member	UCSF Helen Diller Family Comprehensive Cancer Center	
2002 - 2002	Mini-Fellowship,	Genitourinary Pathology, with Dr. Victor Reuter,	Memorial Sloan-Kettering Cancer Center, New York, NY
2002 - present	Director,	Genitourinary Tissue Core,	UCSF Comprehensive Cancer Center
2002 - present	Chair,	Genitourinary Tissue Utilization Committee,	UCSF
2002 - present	Staff Pathologist,	UCSF Department of Anatomic Pathology	
2003 - 2003	Mini-Fellowship,	Genitourinary Pathology, with Dr. Jonathan Epstein,	Johns Hopkins Medical Institutions, Baltimore, MD

2004 - 2004	Co-Director,	Molecular Pathology Laboratory,	UCSF Departments of Anatomic Pathology and Laboratory Medicine
2008 - 2010	Chair,	Southbay Pathology Society (SBPS) Nominating Committee	
2008 - 2014	Associate Director,	NRG Oncology Biospecimen Bank (NRG = NSABP- RTOG-GOG), An NCI Sponsored National Clinical Trial Cooperative Group Resource	
2008 - present	NCI Group Banking Committee (GBC) Regulatory Subcommittee Member		
2008 - present	NCI GBC Access and Marketing Subcommittee Member		
2010 - present	ALLIANCE Pathology Group Cadre Member Pathologist	An NCI Sponsored National Cooperative Group	
2010 - 2012	Director,	Department of Anatomic Pathology Genitourinary Fellowship Program	
2014 - 2017	Interim Director	UCSF Molecular Genetic Pathology Fellowship Program	
2015 - present	NCI Group Banking Committee Executive Committee		

2015 - present	Director	NRG Oncology Biospecimen Bank at UCSF (NRG = NSABP-RTOG- GOG), An NCI Sponsored National Clinical Trial Cooperative Group Resource
2017 - present	Director	UCSF Molecular Genetic Pathology Fellowship Program
2017 - present	Co-Chair, Pathology Committee	NRG Oncology (An NCI Sponsored National Cooperative Group)
2017 - present	Research Strategy Committee Member	NRG Oncology(An NCI Sponsored National Cooperative Group)
-	OTHER EXPERIENCE (Non-pathology)	
1986 - 1990	Research Assistant,	University of North Carolina Chapel Hill Chemistry Department
1993 - 1993	Medical Student Researcher,	Department of Biochemistry, UNC School of Medicine
1993 - 1994	Medical Student Researcher,	Dept. of Maternal and Fetal Med, UNC School of Med.
1994 - 1994	Visiting Scientist,	Department of Biophysics, Beijing Medical University, P.R. China

HONORS AND AWARDS

1984	American Chemical Society	U. of Delaware Analytical Chemistry Award
1994	Howard Hughes Trust Fund Fellowship	University of North Carolina SOM
1994	UNC School of Medicine Foreign Fellowship Award	

1994	Medical Alumni Association Research Fellowship	UNC School of Medicine
1997	Chief Resident	Department of Anatomic Pathology, SF VA Medical Center
1998	Chief Resident	Department of Anatomic Pathology, SF General Hospital
2000	Chief Resident	Department of Laboratory Medicine, SF General Hospital
2000	Travel Award	College of American Pathologists Strategic Science Seminar

KEYWORDS/AREAS OF INTEREST

General Surgical Pathology, Genitourinary Pathology. Urologic Oncology. Molecular Pathology, Molecular Diagnostics and Biomarkers of Malignancies, including tumor antigens and antibodies. Radiology-Pathology Correlations in Genitourinary Malignancy. Tissue Banking

CLINICAL ACTIVITIES

CLINICAL ACTIVITIES SUMMARY

2002 - present Surgical Pathology Clinical Service, UCSF Department of Anatomic Pathology
 (evaluation and case sign-out of UCSF patient surgical and biopsy specimens, intra-operative consultations and frozen sections, outside consultations sent to me from community pathologists; ~25 weeks per year)

2002 - present Surgical Pathology On-Call Service, UCSF Mission Bay Cancer Center, 2 weeks/year

2002 – present Urologic Oncology Tumor Board, UCSF Mission Bay, 24 meetings/year

2002 – 2007 Thoracic Oncology Tumor Board, UCSF Mount Zion Cancer Center, ad hoc, ~3 / year

2004 -- 2004 Co-Director, Molecular Pathology Laboratory, UCSF Clinical Laboratory.

2006 – 2007 Proctor, Molecular Pathology Laboratory Clinical Faculty.

2006 – 2014 Head & Neck Tumor Board, UCSF Mission Bay, ad hoc, ~ 3 / year

2010 – present Proctor, New Surgical Pathology Clinical Faculty.

2015 – present Molecular Pathology Clinical Staff Member, 2 weeks/year

PROFESSIONAL ACTIVITIES

MEMBERSHIPS

1991 - 1992 Member, Japan Applied Physics Society (JAPS)

1992 - 1996 Member, American Medical Student Association (AMSA)

2001 - present Member, US and Canadian Academy of Pathology (USCAP)

2001 - 2010 Fellow, College of American Pathologists (CAP)

- 2001 - 2010 Fellow, American Society of Clinical Pathologists (ASCP)
- 2004 - present Associate Member, South Bay Pathology Society (SBPS)
- 2005 - present Regular member, California Society of Pathologists (CSP)
- 2006 - present Associate Member, American Urologic Association (AUA)
- 2009 - 2010 Regular Member, American Association of Cancer Research (AACR)
- 2014 - 2016 Member, American Society of Clinical Oncology (ASCO)
- 2017 - present American Medical Association (AMA)
- (pending) International Society of Urologic Pathologists (ISUP)
- (pending) Genitourinary Pathology Society (GUPS)

SERVICE TO PROFESSIONAL PUBLICATIONS

- 1992 - 1996 Associate Editor, FAX: The Medical Student Research Journal (UNC-SOM)
- 2002 - present Ad hoc referee, Journal of Urology (more than 30 manuscripts in 13 years)
- 2004 - present Ad hoc referee, J. National Comprehensive Cancer Network (1 manuscript in 1 year)
- 2005 - present Ad hoc referee, American Journal of Pathology (1 manuscript in 1 year)
- 2005 - present Ad hoc referee, Human Pathology (1 manuscript in 1 year)
- 2006 - present Ad hoc Referee, Archives of Pathology and Laboratory Medicine (1 script in 1 year)
- 2007 - 2008 Ad hoc Referee, Journal of Molecular Diagnostic (3 manuscripts in 2 years)
- 2007 - 2011 Ad hoc Referee, European Journal of Urologic Pathology.
- 2010 - present Ad hoc Referee, Urology Journal (6 manuscripts in 3 years)
- 2012 - present Ad hoc Referee, British Journal of Urology International (1 manuscript in 1 year)
- 2013 - present Ad hoc Referee, European Journal of Urology (3-4 manuscripts per year)
- 2014 - 2016 Ad hoc Referee, Clinical Cancer Research (CCR: 2-3 manuscripts per year)
- 2015 - present Ad hoc Referee, Histopathology (1 manuscript in one year)
- 2015 - present Ad hoc Referee, Human Pathology Case Reviews (1 manuscript in one year)
- 2015 - present Ad hoc Referee, PLOS One (8 manuscripts per year).
- 2018 - present Editorial Board Member, Human Pathology

INVITED PRESENTATIONS - INTERNATIONAL

- 2005 3rd Annual Congress of International Drug Discovery Science and Technology (IDDST), Shanghai, PR China
- 2006 4th Annual Congress of IDDST, Dalian, PR China

- 2014 ISUP International Gleason Grading Standardization Convention, Chicago, IL
- 2019 ISUP International Gleason Grading Standardization Convention, Nice, France

INVITED PRESENTATIONS - NATIONAL

- 2008 Pathobiology of Cancer: The Ed Smuckler Memorial Course AACR Snowmass, CO
- 2009 Pathobiology of Cancer: The Ed Smuckler Memorial Course AACR Snowmass, CO
- 2009 RTOG Semi Annual Meeting, Philadelphia, PA (RTOG Tissue Banking Efforts)
- 2010 American College of Osteopathic Pathology, National Meeting, San Francisco, CA
- 2012 RTOG Semi Annual Meeting, Atlanta, GA (Tissue Banks in the Cooperative Groups)
- 2012 RTOG Semi Annual Symposium Organizer, Philadelphia (next Gen Sequencing in Cooperative Group Settings)
- 2013 RTOG Semiannual Meeting, San Diego, CA
- 2013 RTOG Semiannual Meeting, Philadelphia, PA
- 2018 NRG (RTOG) SemiAnnual Meeting CME course on Biobanking, Philadelphia, PA
- 2018 NRG (RTOG) Semi Annual Meeting, Pathology Committee Chair update, Philadelphia, PA
- 2018 NRG (RTOG) Semi Annual Meeting, Pathology Committee Chair update, Phoenix, AZ
- 2019 NRG (RTOG) Semi Annual Meeting, Pathology Committee Chair update, Phoenix, AZ
- 2019 NRG (RTOG) Semi Annual Meeting, Pathology Committee Chair update, Philadelphia, PA
- 2020 NRG (RTOG) Semi Annual Meeting, Pathology Committee Chair update, Houston, TX

INVITED PRESENTATIONS - REGIONAL AND OTHER INVITED PRESENTATIONS

- 2004 Current Issues in Anatomic Pathology, San Francisco, CA
- 2004 UCSF Department of Radiation Oncology Grand Rounds, San Francisco, CA

2004	Southbay Pathology Society Monthly CME Meeting 1-2 per year, Stanford, CA	Speaker
2005	Current Issues in Anatomic Pathology, San Francisco, CA	
2005	City of Hope National Medical Center, Duarte, CA	
2006	Current Issues in Anatomic Pathology, San Francisco, CA	
2006	Beijing Medical University, Beijing, PR China	
2008	Current Issues in Anatomic Pathology, San Francisco, CA	
2010	Current Issues in Anatomic Pathology, San Francisco, CA	
2011	Guest Professor, Department of Pathology, University of Hawaii Medical School	
2012	Current Issues in Anatomic Pathology, San Francisco, CA	
2013	Guest Professor, Grand Rounds, Department of Pathology, Harbor-UCLA Med Ctr.	
2013	Current Issues in Anatomic Pathology, San Francisco, CA	
2014	Current Issues in Anatomic Pathology, San Francisco, CA	
2014	Colorado Society of Clinical Pathologists Stars in the Mountains CME, Vail, CO	
2014	NCI Group Banking Committee Executive Committee Semi-annual Meeting Participant, Columbus, OH	
2014	Canary Foundation PASS and Prostate Cancer Clinical Trials Annual Face-to-Face Participant, Seattle, WA	
2014	UCSF Department of Radiation Oncology Grand Rounds, San Francisco, CA	
2014	Prostate Cancer Foundation Annual Meeting Invited Participant, La Costa, CA	
2015	Current Issues in Anatomic Pathology, San Francisco, CA	Speaker
2015	Guest Professor, Department of Pathology, University of Hawaii Medical School	Speaker
2015	Guest Lecture, Hawaii Society of Pathologists Monthly Meeting, Honolulu, H	Speaker
2015	NCI Group Banking Committee Executive Committee Semi-annual Meeting Participant, Houston, TX	Invited Participant
2015	NCI Group Banking Committee Executive Committee Semi-annual Meeting Participant, San Francisco, CA	Host
2015	Prostate Cancer Foundation Annual Meeting Invited Participant, Washington, DC	Invited Participant

2015	Canary Foundation PASS and Prostate Cancer Clinical Trials Annual Face-to-Face Participant, Stanford, CA	Invited Participant
2016	Current Issues in Anatomic Pathology, San Francisco, CA	Speaker
2016	Guest Host, CAP Introduction to In Vivo Microscopy Interpretation Course, San Francisco, CA	Speaker
2016	NCI Group Banking Committee Executive Committee Semi-annual Meeting Participant, Rochester, MN	Invited Participant
2016	Prostate Cancer Foundation Annual Meeting Invited Participant, La Costa, CA	Invited Participant
2016	Canary Foundation PASS and Prostate Cancer Clinical Trials Annual Face-to-Face Participant, Stanford, CA	Invited Participant
2016	College of American Pathologists House of Delegates Semi-annual Meeting, Nashville, TN	Invited Participant
2016	College of American Pathologists House of Delegates Semi-annual Meeting, Seattle, WA	Invited Participant
2017	Current Issues in Anatomic Pathology, San Francisco, CA	Speaker
2017	Guest Professor, Department of Pathology, University of Hawaii Medical School	Speaker
2017	NCI Group Banking Committee Executive Committee Semi-annual Meeting Participant, Rockville, MD	Invited Participant
2017	NCI Group Banking Committee Executive Committee Semi-annual Meeting Participant, San Francisco, CA	Invited Participant
2017	Prostate Cancer Foundation Annual Meeting Invited Participant, Washington, DC	Invited Participant
2017	Canary Foundation PASS and Prostate Cancer Clinical Trials Annual Face-to-Face Participant, Seattle, WA	Invited Participant
2017	College of American Pathologists House of Delegates Semi-annual Meeting, National Harbor, MD	Invited Participant
2017	College of American Pathologists House of Delegates Semi-annual Meeting, San Antonio, TX	Invited Participant
2018	The Alliance for Clinical Trials Semi-annual meeting GU Pathology Cadre Update, Rosemont, IL	Presenter
2018	The Alliance for Clinical Trials Semi-annual meeting GU Pathology Cadre Update, Rosemont, IL	Presenter
2018	2018 NCI Group Banking Committee Executive Committee Semi-annual Meeting Participant, Saint Louis, MO	Invited Participant
2018	Prostate Cancer Foundation Annual Meeting Invited Participant, La Costa, CA	Invited Participant

2018	Canary Foundation PASS and Prostate Cancer Clinical Trials Annual Face-to-Face Participant, Seattle, WA	Invited Participant
2018	College of American Pathologists House of Delegates Semi-annual Meeting, Vancouver, BC Canada	Invited Participant
2018	College of American Pathologists House of Delegates Semi-annual Meeting, Chicago, IL	Invited Participant
2019	NCI Group Banking Committee Executive Committee Semi-annual Meeting, NRG Biobank Update, Rockville, MD	Speaker
2019	College of American Pathologists House of Delegates Semi-annual Meeting, National Harbor, MD	Invited Participant
2019	Current Issues in Anatomic Pathology, San Francisco, CA	Speaker
2019	The Alliance for Clinical Trials Semi-annual meeting GU Pathology Cadre Update, Rosemont, IL	Speaker
2019	Canary Foundation PASS and Prostate Cancer Clinical Trials Annual Face-to-Face Participant, Stanford, CA	Invited Participant
2019	Prostate Cancer Foundation Annual Meeting Invited Participant, La Costa, CA	Invited Participant
2019	The Alliance for Clinical Trials Semi-annual meeting GU Pathology Cadre Update, Rosemont, IL	Speaker
2020	NCI Group Banking Committee Executive Committee Semi-annual Meeting, NRG Biobank Update, Columbus, OH	Speaker
2020	Current Issues in Anatomic Pathology, San Francisco, CA	Speaker

CONTINUING EDUCATION AND PROFESSIONAL DEVELOPMENT ACTIVITIES

2002	Diagnostic Pathology of Soft Tissue Tumors, Harvard Medical School, Boston, MA
2003	South Bay Pathology Society Monthly Meetings, Palo Alto, CA
2003	Weekends of Pathology, American Society of Clinical Pathology, San Francisco, CA
2003	American Urological Association Annual Meeting, Chicago, IL
2003	Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
2003	California Society of Pathologist's Annual Meeting, San Francisco, CA
2004	Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
2004	South Bay Pathology Society Monthly Meetings, Palo Alto, CA

- 2004 US and Canadian Academy of Pathology (USCAP) Annual Meeting, Vancouver, BC
- 2004 Advances in Urology, UCSF, San Francisco, CA
- 2004 South Bay Pathology Society Annual Spring Meeting, Monterey, CA
- 2004 California Society of Pathologist's Annual Meeting, San Francisco, CA
- 2005 South Bay Pathology Society Annual Spring Meeting, Monterey, CA
- 2005 South Bay Pathology Society Monthly Meetings, Palo Alto, CA
- 2005 Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
- 2006 ASCO Prostate Cancer Symposium, San Francisco, CA
- 2006 South Bay Pathology Society Monthly Meetings, Palo Alto, CA
- 2006 Controversies in Prostate Cancer Detection, UT MDAnderson, Kohala, HI
- 2006 South Bay Pathology Society Annual Spring Meeting, Monterey, CA
- 2006 Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
- 2006 American Society of Clinical Pathology Annual Meeting, Las Vegas, NV
- 2006 California Society of Pathology Annual Meeting, San Francisco, CA
- 2007 Current Controversies in Urologic Oncology, UCSF Dept of Urology, SF, CA
- 2007 South Bay Pathology Society Monthly Meetings, Palo Alto, CA
- 2007 Weekends of Pathology, American Society of Clinical Pathology, Las Vegas, NV
- 2007 Early Stage Prostate Cancer Management, UCSF Dept of Urology, San Francisco, CA
- 2007 US and Canadian Academy of Pathology (USCAP) Annual Meeting, San Diego, CA
- 2007 South Bay Pathology Society Annual Spring Meeting, Monterey, CA
- 2007 Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
- 2007 Association of Molecular Pathology Annual Meeting, Los Angeles, CA
- 2008 ASCO Genitourinary Cancer Symposium, San Francisco, CA
- 2008 South Bay Pathology Society Monthly Meetings, Palo Alto, CA
- 2008 Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
- 2008 South Bay Pathology Society Annual Spring Meeting, San Francisco, CA
- 2008 RTOG Semiannual meeting, San Diego, CA
- 2008 RTOG Semiannual meeting, Philadelphia, PA
- 2008 California Society of Pathology Annual Meeting, Los Angeles, CA

2009 RTOG SemiAnnual Meeting, New Orleans, LA
2009 South Bay Pathology Society Monthly Meetings, Palo Alto, CA
2009 UCSF Department of Urology Annual CME Course, San Francisco, CA
2009 US and Canadian Academy of Pathology (USCAP) Annual Meeting, Boston, MA
2009 South Bay Pathology Society Annual Spring Meeting, Monterey, CA
2009 RTOG SemiAnnual Meeting, Chicago, IL
2010 RTOG SemiAnnual Meeting, Tampa, FL
2010 South Bay Pathology Society Monthly Meetings, Palo Alto, CA
2010 ASCO GU Oncology Symposium, San Francisco, CA
2010 USCAP Annual Meeting, Washington DC
2010 RTOG SemiAnnual Meeting, Philadelphia, PA
2010 Current Issues in Anatomic Pathology, San Francisco, CA
2010 California Society of Pathologists Annual Meeting, San Francisco, CA.
2010 CTRR Annual Symposium, San Francisco, CA
2011 RTOG Semi Annual Meeting, San Diego, CA
2011 South Bay Pathology Society Monthly Meetings, Palo Alto, CA
2011 Current Issues in Anatomic Pathology, San Francisco, CA
2011 RTOG Semi Annual Meeting, Philadelphia, PA
2011 California Society of Pathology Annual Meeting, San Francisco, CA
2012 RTOG Semi Annual Meeting, Atlanta, GA
2012 South Bay Pathology Society Monthly Meetings, Palo Alto, CA
2012 ASCO Genitourinary Symposium, San Francisco, CA
2012 USCAP Annual Meeting, Vancouver, BC, CN
2012 Current Issues in Anatomic Pathology, San Francisco, CA
2012 RTOG Semi Annual Meeting, Philadelphia, PA
2012 Association of Molecular Pathology Annual Meeting, Long Beach, CA
2012 California Society of Pathology Annual Meeting, San Francisco, CA
2013 RTOG Semiannual Meeting, San Diego, CA
2013 South Bay Pathology Society Monthly Meetings, Palo Alto, CA
2013 AUA Annual Meeting, San Diego, CA
2013 Southbay Pathology Society Annual Meeting, Monterey, CA

2013 Current Issues in Anatomic Pathology, San Francisco, CA

2013 RTOG Semiannual Meeting, Philadelphia, PA

2013 California Society of Pathology Annual Meeting (San Francisco, CA)

2013 California Tumor Tissue Registry Semi-Annual Seminar (San Francisco, CA)

2014 NRG (RTOG) Semi Annual Meeting, San Diego, CA

2014 South Bay Pathology Society Monthly Meetings, Palo Alto, CA

2014 ASCO Genitourinary Symposium (San Francisco, CA)

2014 USCAP Annual Meeting (San Diego, CA)

2014 Current Issues in Anatomic Pathology, San Francisco, CA

2014 ASCO Annual Meeting, Chicago, IL

2014 NRG (RTOG) Semi Annual Meeting, Chicago, IL

2014 Colorado Society of Clinical Pathologists Stars in the Mountains, Vail, CO

2014 College of American Pathologists (CAP) Annual Meeting, Chicago, IL

2014 Association of Molecular Pathology (AMP) Annual Meeting, Washington, DC

2014 California Society of Pathology Annual Meeting (San Francisco, CA)

2015 NRG (RTOG) SemiAnnual Meeting, San Diego, CA

2015 South Bay Pathology Society Monthly Meetings, Palo Alto, CA

2015 USCAP Annual Meeting (Boston, MA)

2015 Current Issues in Anatomic Pathology, San Francisco, CA

2015 NRG (RTOG) SemiAnnual Meeting, Denver, CO

2015 College of American Pathologists Annual Meeting, Nashville, TN

2015 The Alliance for Oncology Clinical Trials Fall Meeting, Chicago, IL

2015 California Society of Pathologists Annual Meeting, San Francisco, CA

2016 ASCO Genitourinary Symposium (San Francisco, CA)

2016 South Bay Pathology Society Monthly Meetings, Palo Alto, CA

2016 NRG (RTOG) SemiAnnual Meeting, Atlanta, GA

2016 USCAP Annual Meeting (Seattle, WA)

2016 CAP Introduction to In Vivo Microscopy Interpretation, San Francisco, CA

2016 Current Issues in Anatomic Pathology, San Francisco, CA

2016 NRG (RTOG) SemiAnnual Meeting, Dallas, TX

2016 Association of Molecular Pathology Annual Meeting, Charlotte, NC.

2016 California Society of Pathologists Annual Meeting, San Francisco, CA

2017 NRG (RTOG) SemiAnnual Meeting, Houston, TX

2017 South Bay Pathology Society Monthly Meetings, Palo Alto, CA

2017 USCAP Annual Meeting, San Antonio, TX

2017 Current Issues in Anatomic Pathology, San Francisco, CA

2017 NRG (RTOG) SemiAnnual Meeting, Philadelphia, PA

2017 College of American Pathologists Annual Meeting, National Harbor, MD

2017 The Alliance for Oncology Clinical Trials Fall Meeting, Chicago, IL

2017 California Society of Pathologist, San Francisco, CA

2018 NRG Oncology Semiannual Meeting, Phoenix, AZ

2018 ASCO Genitourinary Cancer Symposium, San Francisco, CA

2018 United States and Canadian Academy of Pathology Annual Meeting, Vancouver, Canada

2018 Alliance Semiannual Meeting, Chicago, IL

2018 Current Issues in Anatomic Pathology, San Francisco, CA

2018 NRG Oncology Meeting, Philadelphia, PA

2018 California Tumor Tissue Registry Meeting, San Francisco, CA

2018 California Society of Pathologist, San Francisco, CA

2019 NRG Oncology Winter Meeting, Pheonix, AZ

2019 ASCO Genitourinary Cancers Symposium, San Francisco, CA

2019 United States and Canadian Academy of Pathology Annual Meeting, National Harbor, Maryland

2019 Current Issues in Anatomic Pathology, San Francisco, CA

2019 NRG Oncology Summer Meeting, Philadelphia, PA

2019 California Society of Pathologist, San Francisco, CA

2019 California Tumor Tissue Registry Meeting, San Francisco, CA

2020 ASCO Genitourinary Cancers Symposium, San Francisco, CA

2020 United States and Canadian Academy of Pathology Annual Meeting, Los Angeles, CA.

2020 Current Issues in Anatomic Pathology, San Francisco, CA

GOVERNMENT AND OTHER PROFESSIONAL SERVICE

2003 - 2008 Representative, Prostate SPORE, InterSPORE Biomarkers Working Group (IPBS)

- 2004 - 2005 Invited Pathologist, Prostate Atrophy Consensus Working Group
- 2005 - present Laboratory Inspector, College of American Pathologists (CAP) (~1 per year).
- 2007 - 2008 Ad Hoc Reviewer, NIH Grants Review Panel "Cooperative Human Tissue Network"
- 2008 - 2010 Chair, Southbay Pathology Society (SBPS) Nominating Committee
- 2008 - present NCI Group Banking Committee (GBC) Regulatory Subcommittee Member
- 2008 - present NCI GBC Access and Marketing Subcommittee Member
- 2009 - 2010 Ad Hoc Reviewer, NIH Contracts Review Panel "CTCs Technology"
- 2010 - 2011 Grant Reviewer, US Veteran's Administration Oncology (A) Grant Review Panel
- 2010 - present Pathology Cadre Member and Case Reviewer, Alliance (NCI Cooperative Group)
- 2010 - present Grant Reviewer, Prostate Cancer Foundation (PCF), Grant Review Panel
- 2012 - 2015 Grant Reviewer, Pennsylvania State Department of Health Cure Grant Program
- 2013 - 2013 Grant Reviewer, Movember Foundation for Men's Health, Grant Review Panel
- 2014 - 2014 ISUP International Prostate Grading Standardization Convention, Chicago, IL
- 2015 - present NCI Group Banking Committee (GBC) Executive Committee
- 2015 - present Grant reviewer, Florida State Tobacco Funds Grant Programs
- 2019 - 2019 ISUP International Prostate Grading Standardization Convention, Nice, France

UNIVERSITY AND PUBLIC SERVICE

SERVICE ACTIVITIES SUMMARY

My service involvement stems from my experience and abilities in genitourinary pathology, Molecular Pathology, and tissue banking. I have become heavily involved in the functioning and support of the tissue resources in the UCSF Comprehensive Cancer Center and the NRG Oncology Clinical Trials Group (formerly known as RTOG; Radiation Therapy Oncology Group), one of the five National Clinical Trials Cooperative Groups for Oncology. This involvement includes oversight of tissue collection, storage and processing, and quality control

measures in order to ensure that the resource is of highest quality without any compromise to the diagnostic utility of these specimens for clinical decision-making. This also involves acting as advisor to, and collaborator with researchers wanting to use tissue resources in their projects. These interactions help optimize effective use of the resource by investigators, and also involve aid in study design and grant proposal preparation. Besides the obvious offshoot into research collaborations and projects, this experience has also led to my involvement in a number of committees (national and local) that directly oversee the management and utilization activities for research tissues, in order to ensure effective collection and use of these limited resources. This has led to recognition beyond UCSF and involves in working groups that are trying to standardize tissue collection and storage protocols across a number of institutions in order to minimize pre-analytical variables that could lead to confounding results in cross-institutional studies. In particular, I am now a member of the NCI Group Banking Committee (GBC) Executive Committee, and a number of subcommittees (regulatory subcommittee and access and marketing subcommittee) composed of a group of 20 national experts in tissue procurement and usage that advises and develops now policies for biospecimen handling in nationally-sponsored oncology clinical trials. The ultimate goal of all of this work is to develop new national standards for tissue collection and processing that will optimize clinical utility of new biomarkers currently under development. This most recently has lead to, as a member of a group of pathologists here at UCSF, being awarded the contract to run the NRG Biospecimen Bank, one of only five NCI funded national cooperative group biospecimen banks in the USA.

My experience in Genitourinary Pathology has reached international recognition, as I am invited to participate in various working groups and conventions that are attempting to standardize Genitourinary Pathology diagnostic criteria (most notably for prostate cancer), I routinely get asked to review manuscripts submitted to international journals, I get invited to present at various national and regional CME courses and academic institutions' grand rounds, and also invited to review grant submissions for various government (US Veterans' Administration, State of Pennsylvania Tobacco Funds, State of Florida Tobacco Funds) and charitable organizations (Prostate Cancer Foundation and Movember Foundation for Men's Health).

I also volunteer as a Certified Laboratory Inspector for the College of American Pathology (CAP) Laboratory Accreditation program, which involves travel to other pathology laboratories in the USA and around the world (e.g. Europe, Asia, China, etc.) to evaluate their quality control, assurance and safety procedures. CAP is now planning to expand into certification processes for Tissue Banks, which will involve similar standards and oversight.

Additional service relates to my experience in molecular pathology, where I was involved in development and planning of a clinical molecular pathology laboratory, and I also served as the Clinical Proctor for a new Director of the Molecular Pathology Laboratory, as well as now proctoring new faculty and clinical instructors in Surgical Pathology Case Sign-out, and acting as the Molecular Genetic pathology Fellowship Program Director.

SCHOOL OF MEDICINE

- HOSPITAL / MEDICAL CENTER SERVICE
- 2002 - present Surgical Pathology Clinical Service, UCSF Department of Pathology, 21 weeks/year.

- 2002 - present Surgical Pathology On-Call Service, UCSF Mount Zion Cancer Center, 7 weeks/year.
- 2002 - present Urologic Oncology Tumor Board, UCSF Mount Zion Cancer Center, 25 meetings/year.
- 2002 - 2006 Thoracic Oncology Tumor Board, UCSF Mount Zion Cancer Center, ad hoc, ~2/year.
- 2004 - 2004 Co-Director, Molecular Pathology Laboratory, UCSF Clinical Laboratory.
- 2006 - 2007 Proctor, Molecular Pathology Clinical Faculty.
- 2006 - 2008 Gynecologic Tumor Board, UCSF Mount Zion Cancer Center, ad hoc, ~ 2 / year.
- 2007 - 2014 Gastrointestinal Tract Tumor Board, UCSF Mount Zion Cancer Center, ~ 2 / year.
- 2010 –2018 Proctor, New Surgical Pathology Clinical Faculty (1 or 2 faculty per year)
- UCSF COMPREHENSIVE CANCER CENTER SERVICE
- 2002 - present Member, Genitourinary Oncology Program
- 2002 - present Chair, UCSF Genitourinary Tissue Utilization Committee
- 2002 - present Director, Genitourinary Oncology Program Tissue Core
- 2002 - 2008 Member, UCSF Prostate SPORE Project and Core Leaders Group
- 2002 - 2015 Member, Tissue Shared Resources Oversight Committee
- 2007 - 2007 Member, Academic Recruitment Search Committee
- 2014 - 2014 Member, UCSF Molecular Tumor Board Planning Committee
- 2014 - 2017 Member, University Tissue Banking Organizational Committee

DEPARTMENTAL SERVICE

- DEPARTMENT OF ANATOMIC PATHOLOGY SERVICE:
- 2002 - 2004 Consultant, Molecular Pathology Laboratory Development
- 2004 - 2004 Member, Department of Anatomic Pathology Faculty Search Committee
- 2006 - 2007 Proctor, Molecular Pathology Clinical Faculty
- 2010 - 2012 Director, Urologic Pathology Fellowship
- 2010 - present Proctor, New Surgical Pathology Clinical Faculty

- 2013 - 2013 Member, Department of Anatomic Pathology Faculty Search Committee
- 2014 - present Interim Director, UCSF Molecular Genetic Pathology Fellowship Program
- 2014 - present Faculty Mentor
- 2015 - 2015 Chair, Department of Anatomic Pathology Faculty Search Committee
- DEPARTMENT OF UROLOGY SERVICE:
- 2008 - present Director, Bimonthly Urology-Pathology Case Correlation Conferences
- 2010 - 2010 Member, Faculty Search Committee
- 2013 - 2013 Member, Faculty Search Committee
- 2014 - 2017 Member, UCSF Prostate SPORE Planning Committee

COMMUNITY AND PUBLIC SERVICE

- 1992 - 1994 CATCH: Coaching Adolescents Towards Careers in Health, UNC-SOM
- 1992 - 1994 STEP: Students Teaching Early Prevention , UNC-SOM Health awareness

PEER REVIEWED PUBLICATIONS

1. **J.P. Simko** and G Oehrlein, "Reactive Ion Etching of Silicon and Silicon Dioxide in CF4 Plasmas containing Hydrogen or C2F4 additives", J. of the Electrochemical Society 138, 2748 (1991).
2. **J.P. Simko**, G.S. Oehrlein and T.M. Mayer, "Removal of Fluorocarbon Residues on CF4/H2 Reactive Ion Etched Silicon Surfaces using a Hydrogen Plasma", J. of the Electrochemical Society 138, 277 (1991).
3. Y.Z. Hu, K.A. Conrad, M. Li, J.W. Andrews, **J.P. Simko** and E.A. Irene, "Studies of Hydrogen Ion Beam Cleaning of Silicon Dioxide from Silicon using in-situ Spectroscopic Ellipsometry and X-ray Photo-electron Spectroscopy", Applied Physics Letters 58, 589 (1991).
4. **J.P. Simko**, T. Meguro, S. Iwai, K. Ozasa, A. Hirata, Y. Aoyagi and T. Sugano, "Direct Observation of Self-limiting Gallium Deposition on Gallium Arsenide during Laser-atomic Layer Epitaxial Processing", Japan Journal of Applied Physics Letters 39, L1518 (1992).
5. **J.P. Simko**, T. Meguro, S. Iwai, K. Ozasa, Y. Aoyagi and T. Sugano, "Surface Photo-absorption Study of the Laser-assisted Atomic Layer Epitaxial Growth Process of Gallium Arsenide", Proceedings of the Second International Symposium on Atomic Layer Epitaxy, June 3-6, 1992, Raleigh, North Carolina, Thin Solid Films 225, 40 (1993).
6. **Simko JP**, Caliendo AM, Hogle K, Versalovic J. Differences in laboratory findings for cerebrospinal fluid specimens obtained from patients with meningitis or encephalitis due to

herpes simplex virus (HSV) documented by detection of HSV DNA. Clin Infect Dis. 2002 Aug 15;35(4):414-9. Epub 2002 Jul 17. PubMed PMID: 12145725.

7. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, **Simko J**, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van Dekken H., "Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors," Hum Mol Genet. 13(13): 1303-13 (2004).
8. Watson JE, Doggett NA, Albertson DG, Andaya A, Chinnaiyan A, Van Dekken H, Ginzinger D, Haqq C, James K, Kamkar S, Kowbel D, Pinkel D, Schmitt L, **Simko JP**, Volik S, Weinberg VK, Paris PL, Collins C., "Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer", Oncogene 23(19):3487-94 (2004). PMID: 15007382
9. Watson JE, Kamkar S, James K, Kowbel D, Andaya A, Paris PL, **Simko J**, Carroll P, McAlhany S, Rowley D, Collins C, "Molecular analysis of WFDC1/ps20 gene in prostate cancer," Prostate 61(2): 192-9 (2004).
10. Retz MM, Sidhu SS, Blaveri E, Kerr SC, Dolganov GM, Lehmann J, Carroll P, **Simko J**, Waldman FM, Basbaum C, "CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells," Int J Cancer 114(2): 182-9 (2005).
11. E Blaveri, **JP Simko**, JE Korkola, JL Brewer, F Baehner, K Mehta, S DeVries, T Koppie, S Pejavar, P Carroll and F Waldman, "Gene Expression Patterns Identify Bladder Cancer Subtypes and Predict Outcome," Clin Cancer Res 11(11): 4044-55 (2005).
12. Master VA, Chi T, **Simko JP**, Weinberg V, Carroll PR, "The independent impact of extended pattern biopsy on prostate cancer stage migration," J Urol 174(5): 1789-93 (2005). PMID: 16217288
13. Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, Pejavar S, Mehta K, Carroll P, **Simko JP**, Waldman FM, "Bladder cancer stage and outcome by array-based comparative genomic hybridization," Clin Cancer Res 11(19 Pt 1): 7012-22 (2005). PMID: 15930339
14. WA Ricke, K Ishii, EA Ricke, **JP Simko**, YZ Wang, SW Hayward, and FR Cunha, "*Steroid Hormones Stimulate Human Prostate Cancer Progression and Metastasis*," Int J Cancer 118(9): 2123-31 (2006).
15. Paris P, Weinberg V, **Simko J**, Andaya A, Albo G, Rubin M, Carroll P, Collins C, "Preliminary Validation of Prostate Cancer Metastatic Risk Biomarkers," Int. J. Biomarkers 20(3): 141-45 (2005).
16. Hom JJ, Coakley FV, **Simko JP**, Qayyum A, Lu Y, Schmitt L, Carroll PR, Kurhanewicz J, "Prostate Cancer: Endorectal MR Imaging and MR Spectroscopic Imaging--Distinction of True-Positive Results from Chance-detected Lesions," Radiology 238(1): 192-9 (2006).
17. Rini BI, Weinberg V, Dunlap S, Elchinoff A, Yu N, Bok R, **Simko J**, Small EJ, "Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma," Cancer 106(3): 566-75 (2006).
18. Sanchez-Mejia RO, Ojemann SG, **Simko J**, Chaudhary UB, Levy J, Lawton MT, "Sacral epithelioid angiosarcoma associated with a bleeding diathesis and spinal epidural hematoma: case report," J Neurosurg Spine 4(3): 246-50 (2006).

19. A M De Marzo , E A Platz , J I Epstein , T Ali , A Billis, T Y Chan , L Cheng, M Datta, L Egevad, D Ertoy-Baydar , X Farre , S W Fine , K A Iczkowski, M Ittmann, B S Knudsen, M Loda, A Lopez-Beltran, C Magi-Galluzzi, G Mikuz , R Montironi, E Pikarsky, G Pizov, M A Rubin, H Samaratinga, T Sebo, I A Sesterhenn, RB Shah, S Signoretti, **J Simko** ,G Thomas, P Troncoso, T Tsuzuki, G JLH van Leenders, XJ Yang, M Zhou, W D Figg, A Hoque and M S Lucia, "A Working Group Classification of Focal Prostate Atrophy Lesions," *Am. J. Surg. Pathol.* 30(10): 1281-91 (2006).
20. M Swanson, A Zektzer, ZL Tabatabai, **J Simko**, S Jarso, K Keshari, L Schmitt, P Carroll, K Shinohara, D Vigneron, and J Kurhanewicz, "Quantitative Analysis of Prostate Metabolites using ¹H HR-MAS Spectroscopy," *Mag Res Med* 55(6): 1257-64 (2006).
21. B. Rini, E. Jaeger, N. Sein, K. Fong, K. Chew, **J. Simko** and F. Waldman, "Clinical Response to VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma: Impact of Patient Characteristics and VHL Gene Status," *Br. J. Urol. Int.* 98(4): 756-62 (2006).
22. Ruan W, Sassoan A, An F, **Simko JP**, Liu B, "Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection," *Mol Cell Proteomics* 5(12) 2364-73 (2006).
23. PL Paris, MD Hofer, G Albo, R Kuefer, JE Gschwend, RE Hautmann, J Fridyland, **JP Simko**, PR Carroll, MA Rubin, and C Collins,"Genomic profiling of hormone naïve lymph node metastases in patients with prostate cancer," *Neoplasia* 8(12): 1083-9 (2006).
24. Ryan C, Haqq C, **Simko J**, Chan J, Weinberg V, Goldfine I, "Expression of insulin-like growth factor 1 receptor in local and metastatic prostate cancer," *Uro. Oncol* 25(2): 134-40 (2007).
25. Hom JJ, Coakley FV, **Simko JP**, Lu Y, Qayyum A, Westphalen A, Schmitt L, Carroll PR, Kurhanewicz J. "High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features," *Radiology* 242(2): 483-9 (2007).
26. W. Nau, E. Bass, C. Diederich, W. Ferrier, **J. Simko**, R. Pelligrino, J. Sutton and R. Shu, "Intradiscal thermal Therapy Using Interstitial Ultrasound: An In Vivo Feasibility Study in Ovine Cervical Spine," *Spine* 32(5): 503-11 (2007).
27. Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, **Simko J**, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA, "Morphological features of TMPRSS2-ERG gene fusion prostate cancer," *J Pathol* 212(1): 91-101 (2007).
28. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, **Simko J**, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA, "TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion," *Am J Surg Pathol* 31(6): 882-888 (2007).
29. Jancelewicz T, **Simko J**, Lee H, "Obstructing ileal duplication cyst infected with Salmonella in a 2-year-old boy: a case report and review of the literature," *J Pediatr Surg* 42(5): E19-21 (2007).
30. Liu B, Conrad F, Roth A, Drummond DC, **Simko JP**, Marks JD, "Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer," *J Mol Med* 85(10): 1113-23 (2007).
31. Westphalen AC, Coakley FV, Qayyum A, Swanson M, **Simko JP**, Lu Y, Zhao S, Carroll PR, Yeh BM, Kurhanewicz J, "Peripheral zone prostate cancer: accuracy of different

- interpretative approaches with MR and MR spectroscopic imaging," *Radiology* 246(1): 177-84 (2008).
32. D. Ornish, M Magbanua, G Weidner, V Weinberg, C Kemp, C Green, M Mattie, R Marlin, **J Simko**, K Shinohara, C Haqq and P Carroll, "Changes in prostate Gene expression in men undergoing an intensive nutrition and lifestyle intervention," *PNAS* 105(24): 8369-74 (2008).
 33. Swanson MG, Keshari KR, Tabatabai ZL, **Simko JP**, Shinohara K, Carroll PR, Zektzer AS, Kurhanewicz J, "Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy," *Magn Reson Med* 60(1): 33-40 (2008).
 34. Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, **Simko J**, Bismar TA, Ayala G, Shah RB, Loda M, Rubin MA, "Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications," *Clin Cancer Res* 14(11): 3380-5 (2008).
 35. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, **Simko J**, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R, "von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma," *J Urol* 180(3): 860-5 (2008).
 36. Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, **Simko JP**, Shinohara K, Nelson SJ, Vigneron DB, Gribbestad IS, Kurhanewicz J, "Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues," *Magn Reson Med* 60(3): 510-6 (2008). PMID: 18727052
 37. Paris PL, Sridharan S, Hittelman AB, Kobayashi Y, Perner S, Huang G, **Simko J**, Carroll P, Rubin MA, Collins C, "An oncogenic role for the multiple endocrine neoplasia type 1 gene in prostate cancer," *Prostate Cancer Prostatic Dis.* 12(2): 184-91 (2009).
 38. C Crane, A Panner, JC Murray, SP Wilson, H Xu, L Chen, JP **Simko**, FM Waldman, RO Pieper and AT Parsa, "P(i)3 kinase is associated with a mechanism of immunoresistance in breast and prostate cancer," *Oncogene* 28(2): 306-12 (2009).
 39. Paris PL, Kobayashi Y, Zhao Q, Zeng W, Sridharan S, Fan T, Adler HL, Yera ER, Zarrabi MH, Zucker S, **Simko J**, Chen WT, Rosenberg J, "Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer," *Cancer Lett* 277(2): 164-73 (2009).
 40. Torabian SZ, de Semir D, Nosrati M, Bagheri S, Dar AA, Fong S, Liu Y, Federman S, **Simko J**, Haqq C, Debs RJ, Kashani-Sabet M, "Ribozyme-mediated targeting of I κ B γ inhibits melanoma invasion and metastasis," *Am J Pathol* 174(3): 1009-16 (2009).
 41. Conti SL, Dall'era M, Fradet V, Cowan JE, **Simko J**, Carroll PR, "Pathological outcomes of candidates for active surveillance of prostate cancer," *J Urol* 181(4): 1628-33 (2009).
 42. Kashani-Sabet M, Rangel J, Torabian S, Nosrati M, **Simko J**, Jablons DM, Moore DH, Haqq C, Miller JR 3rd, Sagebiel RW, "A multi-marker assay to distinguish malignant melanomas from benign nevi," *Proc Natl Acad Sci U S A.* 106(15): 6268-72 (2009).

43. Hou Y, DeVoss J, Dao V, Kwek S, **Simko JP**, McNeel DG, Anderson MS, Fong L, "An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans," *J Clin Invest* 119(7): 2031-41 (2009). PMID: 19603556
44. Westphalen AC, Coakley FV, Kurhanewicz J, Reed G, Wang ZJ, **Simko JP**, "Mucinous adenocarcinoma of the prostate: MRI and MR spectroscopy features," *Am J Roentgenol* 193(3): W238-43 (2009). PMID: 19696265
45. Kashani-Sabet M, Venna S, Nosrati M, Rangel J, Sucker A, Egberts F, Baehner FL, **Simko J**, Leong SP, Haqq C, Hauschild A, Schadendorf D, Miller JR 3rd, Sagebiel RW, "A multimarker prognostic assay for primary cutaneous melanoma," *Clin Cancer Res* 15(22): 6987-92 (2009).
46. Paris PL, Weinberg V, Albo G, Roy R, Burke C, **Simko J**, Carroll P, Collins C, "A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer," *Clin Cancer Res* 16(1): 195-202 (2010).
47. Santos CF, Kurhanewicz J, Tabatabai ZL, **Simko JP**, Keshari KR, Gbegnon A, Santos RD, Federman S, Shinohara K, Carroll PR, Haqq CM, Swanson MG, "Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy," *NMR Biomed* 23(4): 391-8 (2010). PMID: 20033906
48. Vagefi PA, Klein I, Gelb B, Hameed B, Moff SL, **Simko JP**, Fix OK, Eilers H, Feiner JR, Ascher NL, Freise CE, Bass NM, "Emergent Orthotopic Liver Transplantation for Hemorrhage from a Giant Cavernous Hepatic Hemangioma: Case Report and Review," *J Gastrointest Surg* 15(1): 209-14 (2011). PMID: 20549381
49. Dall'era MA, Cowan JE, **Simko J**, Shinohara K, Davies B, Konety BR, Meng MV, Perez N, Greene K, Carroll PR, "Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment," *BJU Int* 107(8): 1232-7 (2011).
50. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, **Simko JP**, Shinohara K, Carroll PR, "The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer," *J Urol* 185(5): 1656-60 (2011). PMID: 21419438
51. Whitson JM, Porten SP, Cowan JE, **Simko JP**, Cooperberg MR, Carroll PR, "Factors associated with downgrading in patients with high grade prostate cancer," *Urol Oncol*. 2011 Apr 7.
52. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stöppler H, **Simko J**, Hilton JF, Carroll P, Blleloch R, "Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients," *Cancer Res* 71(2): 550-60 (2011).
53. Chan JM, Weinberg V, Magbanua MJ, Sosa E, **Simko J**, Shinohara K, Federman S, Mattie M, Hughes-Fulford M, Haqq C, Carroll PR, "Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer," *Cancer Causes Control* 22(1): 141-50 (2011).
54. McKenney JK, **Simko J**, Bonham M, True LD, Troyer D, Hawley S, Newcomb LF, Fazli L, Kunju LP, Nicolas MM, Vakar-Lopez F, Zhang X, Carroll PR, Brooks JD; Canary/Early

- Detection Research Network Prostate Active Surveillance Study Investigators, "The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study," *J Urol* 186(2): 465-9 (2011).
55. Jalas JR, Vemula S, Bezrookove V, Leboit PE, **Simko JP**, Bastian BC, "Metastatic melanoma with striking adenocarcinomatous differentiation illustrating phenotypic plasticity in melanoma," *Am J Surg Pathol* 35(9): 1413-8 (2011).
 56. Magbanua MJ, Roy R, Sosa EV, Weinberg V, Federman S, Mattie MD, Hughes-Fulford M, **Simko J**, Shinohara K, Haqq CM, Carroll PR, Chan JM, "Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation," *PLoS One*. 2011;6(9):e24004. Epub 2011 Sep 1.
 57. Ray M, Hostetter DR, Loeb CR, **Simko J**, Craik CS, "Inhibition of Granzyme B by PI-9 protects prostate cancer cells from apoptosis," *Prostate*. 2012 Jun 1;72(8):846-55. doi: 10.1002/pros.21486. Epub 2011 Sep 14.
 58. Chen L, Hong C, Chen EC, Yee SW, Xu L, Almof EU, Wen C, Fujii K, Johns SJ, Stryke D, Ferrin TE, **Simko J**, Chen X, Costello JF, Giacomini KM, "Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3," *Pharmacogenomics J*. 2012 Jan 10. doi: 10.1038/tbj.2011.60.
 59. Magbanua MJ, Sosa EV, Scott JH, **Simko J**, Collins C, Pinkel D, Ryan CJ, Park JW, "Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer," *BMC Cancer*. 2012 Feb 28;12(1):78.
 60. Busch S, Hatridge M, Mößle M, Myers W, Wong T, Mück M, Chew K, Kuchinsky K, **Simko J**, Clarke J, "Measurements of T(1) -relaxation in ex vivo prostate tissue at 132 μ T," *Magn Reson Med*. 2012 Apr;67(4):1138-45. doi: 10.1002/mrm.24177. Epub 2012 Jan 31.
 61. Ausborn NL, Le QT, Bradley JD, Choy H, Dicker AP, Saha D, **Simko J**, Story MD, Torossian A, Lu B, "Molecular Profiling to Optimize Treatment in Non-Small Cell Lung Cancer: A Review of Potential Molecular Targets for Radiation Therapy by the Translational Research Program of the Radiation Therapy Oncology Group," *Int J Radiat Oncol Biol Phys*. 2012 Apr 18. [Epub ahead of print]
 62. Ross HM, Kryvenko ON, Cowan JE, **Simko JP**, Wheeler TM, Epstein JI, "Do Adenocarcinomas of the Prostate With Gleason Score (GS) \leq 6 Have the Potential to Metastasize to Lymph Nodes?," *Am J Surg Pathol*. 2012 Apr 22. PMID: 22531173
 63. Hayes GM, **Simko J**, Holochwost D, Kuchinsky K, Busch R, Misell L, Murphy EJ, Carroll PR, Chan JM, Shinohara K, Hellerstein MK, "Regional Cell Proliferation in Microdissected Human Prostate Specimens After Heavy Water-Labeling in vivo: Correlation With Prostate Epithelial Cells Isolated From Seminal Fluid," *Clin Cancer Res*. 2012 May 2.
 64. Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, **Simko JP**, Small EJ, Fong L, "Diversity of antigen-specific responses induced in vivo with ctla-4 blockade in prostate cancer patients", *J Immunol* 189(7): 3759-66 (2012). PMID: 22956585
 65. Cooperberg MR, **Simko JP**, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP, Stone S, Carroll PR, "Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort," *J Clin Oncol* 31(11): 1428-34 (2013). PMID: 23460710

66. Hawley S, Fazli L, McKenney JK, **Simko J**, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E, Tenggara I, Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, Feng Z, True LD, Brooks JD, "A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray," *Adv Anat Pathol* 20(1): 39-44 (2013).
67. Ducker GS, Atreya CE, **Simko JP**, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS, "Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors," *Oncogene*. 2013 Apr 1. PMID: 23542178
68. Odisho AY, Washington SL 3rd, Meng MV, Cowan JE, **Simko JP**, Carroll PR, "Benign Prostate Glandular Tissue at Radical Prostatectomy Surgical Margins," *Urology* 82(1) 154-9 (2013). PMID: 23522995
69. Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, **Simko JP**, Garraway LA, Febbo PG, "Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy," *Prostate Cancer Prostatic Dis*. 2013 Dec 24. doi: 10.1038/pcan.2013.37. [Epub ahead of print] PMID: 24366412
70. Hosgood HD 3rd, Pao W, Rothman N, Hu W, Pan YH, Kuchinsky K, Jones KD, Xu J, Vermeulen R, **Simko J**, Lan Q, "Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning," *Respir Med* 107(11): 1755-62 (2013).
71. Stieglitz E, Hsiang MS, **Simko JP**, Hirose S, Goldsby RE, "Pulmonary Coccidiomycosis Masquerading as Refractory Metastatic Ewing Sarcoma," *J Pediatr Hematol Oncol* 36(1): E57-60 (2014). PMID: 23588326
72. Starobinets O, Guo R, **Simko JP**, Kuchinsky K, Kurhanewicz J, Carroll PR, Greene KL, Noworolski SM. "Semiautomatic registration of digital histopathology images to in vivo MR images in molded and unmolded prostates", *J Magn Reson Imaging*. 2014 May;39(5):1223-9. doi: 10.1002/jmri.24287. Epub 2013 Oct 17. PMID: 24136783
73. Anwar M, Westphalen AC, Jung AJ, Noworolski SM, **Simko JP**, Kurhanewicz J, Roach M 3rd, Carroll PR, Coakley FV, "Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: quantitative analysis of imaging contour compared to whole-mount histopathology," *Radiother Oncol* 110(2): 303-8 (2014). PMID: 24444524
74. Magbanua MJ, Richman EL, Sosa EV, Jones LW, **Simko J**, Shinohara K, Haqq CM, Carroll PR, Chan JM, "Physical activity and prostate gene expression in men with low-risk prostate cancer," *Cancer Causes Control* 25(4): 515-23 (2014). PMID: 24504435
75. Klein EA, Cooperberg MR, Magi-Galluzzi C, **Simko JP**, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR, "A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling," *Eur Urol*. 2014 May 16. pii: S0302-2838(14)00414-X. doi: 10.1016/j.eururo.2014.05.004. [Epub ahead of print] PMID: 24836057
76. Wang SY, Shiboski S, Belair CD, Cooperberg MR, **Simko JP**, Stoppler H, Cowan J, Carroll PR, Bilelloch R, "miR-19, miR-345, miR-519c-5p Serum Levels Predict Adverse Pathology

- in Prostate Cancer Patients Eligible for Active Surveillance," PLoS One 9(6):e98597 (2014). PMID: 24893170
77. Jung AJ, Westphalen AC, Kurhanewicz J, Wang ZJ, Carroll PR, **Simko JP**, Coakley FV, "Clinical utility of endorectal MRI-guided prostate biopsy: preliminary experience, "J Magn Reson Imaging 40(2): 314-23 (2014). PMID: 24924999
78. Walker EJ, **Simko JP**, Ko AH, "Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor," Anticancer Res 34(7): 3629-34 (2014). PMID: 24982379
79. Siegel EM, Eschrich S, Winter K, Riggs B, Berglund A, Ajidahun A, **Simko J**, Moughan J, Ajani J, Magliocco A, Elahi A, Hoffe S, Shibata D, "Epigenomic Characterization of Locally Advanced Anal Cancer: A Radiation Therapy Oncology Group 98-11 Specimen Study," Dis Colon Rectum 57(8): 941-957 (2014). PMID: 25003289
80. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, **Simko J**, Sheikh NA, Sims RB, Frohlich MW, Small EJ, "Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer," J Natl Cancer Inst. 2014 Sep 24;106(11). PMID:25255802
81. Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng MV, **Simko JP**, Cooperberg MR, Carroll PR, "Extended Follow-Up and Risk Factors for Disease Reclassification from a Large Active Surveillance Cohort for Localized Prostate Cancer," J Urol. 2014 Sep 24.[Epub ahead of print] PMID:25261803
82. Raleigh DR, Hsu IC, Braunstein S, Chang AJ, **Simko JP**, Roach M 3rd, "Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy," Brachytherapy 14(2): 185-8 (2015). PMID: 25533416
83. Walker EJ, **Simko JP**, Nakakura EK, Ko AH, "A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer," J Gastrointest Oncol. 2014 Dec;5(6):E88-95. doi: 10.3978/j.issn.2078-6891.2014.051.
84. Hope TA, Aggarwal R, **Simko JP**, VanBrocklin HF, Ryan CJ, "Somatostatin imaging of neuroendocrine-differentiated prostate cancer," Clin Nucl Med 40(6): 540-1 (2015). PMID: 25783510
85. Troyer DA, Jamaspishvili T, Wei W, Feng Z, Good J, Hawley S, Fazli L, McKenney JK, **Simko J**, Hurtado-Coll A, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Squire JA, "A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer," Prostate. 2015 May 4. doi: 10.1002/pros.23003. [Epub ahead of print], PMID: 25939393
86. Jalloh M, Leapman MS, Cowan JE, Shinohara K, Greene KL, Roach M III, Chang AJ, Chan JM, **Simko JP**, Carroll PR, "Patterns of Local Failure Following Radiation Therapy for Prostate Cancer," J Urol (2015). (epub ahead of print) 10.1016/j.juro.2015.04.111.
87. Brooks JD, Wei W, Hawley S, Auman H, Newcomb L, Boyer H, Fazli L, **Simko J**, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, McKenney JK, "Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients," PLoS One 10(7): e0132343 (2015). PMID: 26172920

88. Belair CD, Paikari A, Moltzahn F, Shenoy A, Yau C, Dall'Era M, **Simko J**, Benz C, Blleloch R, "DGCR8 is essential for tumor progression following PTEN loss in the prostate," *EMBO Rep.* 2015 Jul 23. pii: e201439925. [Epub ahead of print] PMID: 26206718
89. Cancer Genome Atlas Research Network (132 authors), "The Molecular Taxonomy of Primary Prostate Cancer," *Cell* 163(4): 1011-25 (2015). PMID: 26544944
90. Newcomb LF, Thompson IM Jr, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, **Simko J**, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW; Canary PASS Investigators, "Outcomes of Active Surveillance for the Management of Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort," *J Urol.* 2015 Aug 29 [Epub ahead of print] PMID: 26327354
91. Nordström T, Van Blarigan EL, Ngo V, Roy R, Weinberg V, Song X, **Simko J**, Carroll PR, Chan JM, Paris PL, "Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer," *Prostate.* 2015 Nov 20. doi: 10.1002/pros.23125. [Epub ahead of print]
92. Brand TC, Zhang N, Crager MR, Maddala T, Dee A, Sesterhenn IA, **Simko JP**, Cooperberg MR, Srivastava S, Rosner IL, Chan JM, Febbo PG, Carroll PR, Cullen J, Lawrence HJ, "Patient-Specific Meta-Analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score," *Urology.* 2015 Dec 23. pii: S0090-4295(15)01142-5. doi: 10.1016/j.urology.2015.12.008. [Epub ahead of print]
93. Kim HL, Halabi S, Li P, Mayhew G, **Simko J**, Nixon AB, Small EJ, Rini B, Morris MJ, Taplin ME, George D; Alliance for Clinical Trials in Oncology, "A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance)," *EBioMedicine.* 2015 Sep 8;2(11):1814-20. doi: 10.1016/j.ebiom.2015.09.012. eCollection 2015 Nov. PMID: 26870806
94. Knudsen BS, Kim HL, Erho N, Shin H, Alshalalfa M, Lam LL, Tenggara I, Chadwich K, Van Der Kwast T, Fleshner N, Davicioni E, Carroll PR, Cooperberg MR, Chan JM, **Simko JP**, "Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens," *J Mol Diagn* 18(3): 395-406 (2016). PMID: 26945428
95. Lindquist KJ, Paris PL, Hoffmann TJ, Cardin NJ, Kazma R, Mefford JA, **Simko JP**, Ngo V, Chen Y, Levin AM, Chitale D, Helfand BT, Catalona WJ, Rybicki BA, Witte JS, "Mutational Landscape of Aggressive Prostate Tumors in African American Men," *Cancer Res.* 2016 Feb 26. [Epub ahead of print] PMID: 26921337
96. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; **Grading Committee**, "The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System," *Am J Surg Pathol* 40(2): 244-52 (2016). PMID: 26492179
97. Bonde AA, Korngold EK, Foster BR, Westphalen AC, Pettersson DR, Troxell ML, **Simko JP**, Coakley FV, "Prostate cancer with a pseudocapsule at MR imaging: a marker of high grade and stage disease?," *Clin Imaging* 40(3): 365-9 (2016). PMID: 27133669

98. Tretiakova MS, Wei W, Boyer HD, Newcomb LF, Hawley S, Auman H, Vakar-Lopez F, McKenney JK, Fazli L, **Simko J**, Troyer DA, Hurtado-Coll A, Thompson IM Jr, Carroll PR, Ellis WJ, Gleave ME, Nelson PS, Lin DW, True LD, Feng Z, Brooks JD, "Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies," *Prostate Cancer Prostatic Dis.* 2016 May 3. doi: 10.1038/pcan.2016.12. [Epub ahead of print] PMID: 27136741
99. Lotan TL, Wei W, Ludkovski O, Morais CL, Guedes LB, Jamaspishvili T, Lopez K, Hawley ST, Feng Z, Fazli L, Hurtado-Coll A, McKenney JK, **Simko J**, Carroll PR, Gleave M, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Lance R, Troyer D, Squire JA, "Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH," *Mod Pathol* 29(8): 904-14 (2016). PMID: 27174589
100. Li Y, Mongan J, Behr SC, Sud S, Coakley FV, **Simko J**, Westphalen AC, "Beyond Prostate Adenocarcinoma: Expanding the Differential Diagnosis in Prostate Pathologic Conditions," *Radiographics.* 2016 Jul-Aug;36(4):1055-75. doi: 10.1148/rg.2016150226. Epub 2016 Jun 17. PMID: 27315446
101. Brooks JD, Wei W, Pollack JR, West RB, Shin JH, Sunwoo JB, Hawley SJ, Auman H, Newcomb LF, **Simko J**, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L, "Loss of expression of AZGP1 is associated with worse clinical outcomes in a multi-institutional radical prostatectomy cohort," *Prostate.* 2016 Jun 21. doi: 10.1002/pros.23225. [Epub ahead of print] PMID: 27325561
102. Choi JY, Yang J, Noworolski SM, Behr S, Chang AJ, **Simko JP**, Nguyen HG, Carroll PR, Kurhanewicz J, Seo Y, "18F Fluorocholine Dynamic Time-of-Flight PET/MR Imaging in Patients with Newly Diagnosed Intermediate- to High-Risk Prostate Cancer: Initial Clinical-Pathologic Comparisons," *Radiology.* 2016 Aug 11:160220. [Epub ahead of print] PMID: 27513849
103. Lotan TL, Wei W, Morais CL, Hawley ST, Fazli L, Hurtado-Coll A, Troyer D, McKenney JK, **Simko J**, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD, "PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer," *Eur Urol Focus* 2(2): 180-188 (2016). PMID: 27617307
104. McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, Fazli L, **Simko J**, Hurtado-Coll A, Troyer DA, Tretiakova MS, Vakar-Lopez F, Carroll PR, Cooperberg MR, Gleave ME, Lance RS, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD, "Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort," *Am J Surg Pathol.* 2016 Sep 15. [Epub ahead of print] PMID: 27635949
105. Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, **Simko JP**, Carroll PR, Small EJ, Fong L, "Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer," *Cancer Immunol Res.* 2016 Sep 29. PMID: 27688020
106. Eminaga O, Wei W, Hawley SJ, Auman H, Newcomb LF, **Simko J**, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L, Brooks JD, "MUC1 Expression by Immunohistochemistry Is Associated

- with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study," *PLoS One* 11(11):e0165236. doi: 10.1371/journal.pone.0165236. eCollection 2016 Nov 15. PMID: 27846218
107. Emami NC, Leong L, Wan E, Van Blarigan EL, Cooperberg MR, Tenggara I, Carroll PR, Chan JM, Witte JS, **Simko JP**, "Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy," *Prostate* 77(4): 425-434 (2017) . doi: 10.1002/pros.23283. Epub 2016 Nov 30. PMID: 27900799
 108. Leapman MS, Cowan JE, **Simko J**, Roberge G, Stohr BA, Carroll PR, Cooperberg MR, "Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes," *Eur Urol*. 2016 Dec 8. pii: S0302-2838(16)30884-3. doi: 10.1016/j.eururo.2016.11.032. [Epub ahead of print]PMID: 27940155
 109. 109. Sirohi D, Smith SC, Epstein JI, Balzer BL, **Simko JP**, Balitzer D, Benhamida J, Kryvenko ON, Gupta NS, Paluru S, da Cunha IW, Leal DN, Williamson SR, de Peralta-Venturina M, Amin MB, "Pericytic Tumors of the Kidney - A Clinicopathologic Analysis of 17 Cases," *Hum Pathol*. 2017 Apr 21. pii: S0046-8177(17)30119-3. doi: 10.1016/j.humpath.2017.04.005. [Epub ahead of print]/> PMID: 28438616
 110. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; **TCGA Research Network**, Weinstein JN, Kwiatkowski DJ, Lerner SP, "Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer," *Cell*. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5. PMID: 28988769
 111. Starobinets O, **Simko JP**, Kuchinsky K, Kornak J, Carroll PR, Greene KL, Kurhanewicz J, Noworolski SM. " Characterization and stratification of prostate lesions based on comprehensive multiparametric MRI using detailed whole-mount histopathology as a reference standard." *NMR Biomed*. 2017 Dec;30(12). doi: 10.1002/nbm.3796. Epub 2017 Sep 29. PMID: 28961382
 112. Sirohi D, Garg K, **Simko JP**, Grenert JP. "Renal NUT carcinoma: a case report." *Histopathology*. 2018 Feb;72(3):528-530. doi: 10.1111/his.13368. Epub 2017 Nov 7. PMID: 28837236
 113. Lawrence YR, Moughan J, Magliocco AM, Klimowicz AC, Regine WF, Mowat RB, DiPetrillo TA, Small W Jr, **Simko JP**, Golan T, Winter KA, Guha C, Crane CH, Dicker AP. " Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704." *Cancer*. 2018 Feb 1;124(3):491-498. doi: 10.1002/cncr.31058. Epub 2017 Oct 20. PMID: 29053185
 114. Sahoo D, Wei W, Auman H, Hurtado-Coll A, Carroll PR, Fazli L, Gleave ME, Lin DW, Nelson PS, **Simko J**, Thompson IM, Leach RJ, Troyer DA, True LD, McKenney JK, Feng Z, Brooks JD, "Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer," *Oncotarget* 9(5): 6550-6561 (2018). PMID: 29464091

115. Tzou DT, Cadwell C, **Simko JP**, Chi T, Stoller ML. "Management of Inverted Papilloma During Holmium Laser Enucleation of the Prostate." *Urology*. 2018 Jun;116:e5-e6. doi: 10.1016/j.urology.2018.01.009. Epub 2018 Mar 12. PMID: 29545053
116. Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, Hess J, Ma S, Chiotti KE, McLellan M, Sofia HJ, Hutter C, Getz G, Wheeler D, Ding L; MC3 Working Group; **Cancer Genome Atlas Research Network**, "Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines," *Cell Syst*. 6(3): 271-281.e7 (2018). PMID: 29596782
117. Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Bernard B, Grandori C; **Cancer Genome Atlas Network**, "Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas," *Cell Syst*. 6(3): 282-300.e2 (2018). PMID: 29596783
118. Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N; **Cancer Genome Atlas Research Network**, Sanchez Y, Greene CS, "Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas," *Cell Rep*. 23(1): 172-180.e3 (2018). PMID: 29617658
119. Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, Samaras D, Shroyer KR, Zhao T, Batiste R, Van Arnam J; **Cancer Genome Atlas Research Network**, Shmulevich I, Rao AUK, Lazar AJ, Sharma A, Thorsson V, "Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images," *Cell Rep*. 23(1): 181-193.e7 (2018). PMID: 29617659
120. Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK; **Cancer Genome Atlas Research Network**, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C, "Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas," *Cell Rep*. 23(1): 194-212.e6 (2018). PMID: 29617660
121. Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, Sun Y, Yao F, Li J, Zhang H, Liu J, Shriver CD, Hu H; **Cancer Genome Atlas Research Network**, Piwnicka-Worms H, Ma L, Liang H, "Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types," *Cell Rep*. 23(1): 213-226.e3 (2018). PMID: 29617661
122. Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L, Yu L, Sun SQ; Fusion Analysis Working Group; **Cancer Genome Atlas Research Network**, Chen K, Lazar AJ, Fields RC, Wendl MC, Van Tine BA, Vij R, Chen F, Nykter M, Shmulevich I, Ding L, "Driver Fusions and Their Implications in the Development and Treatment of Human Cancers," *Cell Rep*. 23(1): 227-238.e3 (2018). PMID: 29617662
123. Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Shmulevich I;

- Cancer Genome Atlas Research Network**, Monnat RJ Jr, Xiao Y, Wang C, "Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas," Cell Rep. 23(1): 239-254.e6 (2018). PMID: 29617664
124. Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, Wang Y, Cheng F, Tan L, Mojumdar K, Du D, Ge Z, Li J, Thomas GV, Birsoy K, Liu L, Zhang H, Zhao Z, Marchand C, Weinstein JN; **Cancer Genome Atlas Research Network**, Bathe OF, Liang H, "Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers," Cell Rep. 23(1): 255-269.e4 (2018). PMID: 29617665
125. Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, Zhao Y, Climente-González H, Chai S, Wang F, Varghese R, Huang M, Liang WW, Wyczalkowski MA, Sengupta S, Li Z, Payne SH, Fenyő D, Miner JH, Walter MJ; **Cancer Genome Atlas Research Network**, Vincent B, Eyraas E, Chen K, Shmulevich I, Chen F, Ding L, "Systematic Analysis of Splice-Site-Creating Mutations in Cancer," Cell Rep. 23(1): 270-281.e3 (2018). PMID: 29617666
126. Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, Smith PG; **Cancer Genome Atlas Research Network**, Buonamici S, Yu L, "Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types," Cell Rep. 23(1): 282-296.e4 (2018). PMID: 29617667
127. Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS; **Cancer Genome Atlas Research Network**, Sood AK, Gunaratne PH, Sumazin P, "Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context," Cell Rep. 23(1): 297-312.e12 (2018). PMID: 29617668
128. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; **Cancer Genome Atlas Research Network**, Spellman PT, Rathmell WK, Linehan WM, "The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma," Cell Rep. 23(1): 313-326.e5 (2018). PMID: 29617669
129. Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ; **Cancer Genome Atlas Research Network**, Cherniack AD, Beroukhim R, Meyerson M, "Genomic and Functional Approaches to Understanding Cancer Aneuploidy," Cancer Cell 33(4): 676-689.e3 (2018). PMID: 29622463
130. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N; **Cancer Genome Atlas Research Network**, Weinstein JN, Mills GB, Levine DA, Akbani R, "A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers," Cancer Cell 33(4): 690-705 (2018). PMID: 29622464

131. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S; **Cancer Genome Atlas Research Network**, Xie W, Yang D, "lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer," *Cancer Cell* 33(4): 706-20 (2018). PMID: 29622465
132. Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidfar F, Bowlby R, Islam M, Kim J, Chatila W, Akbani R, Kanchi RS, Rabkin CS, Willis JE, Wang KK, McCall SJ, Mishra L, Ojesina AI, Bullman S, Peadarallu CS, Lazar AJ, Sakai R; **Cancer Genome Atlas Research Network**, Thorsson V, Bass AJ, Laird PW, "Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas," *Cancer Cell* 33(4): 721-735 (2018). PMID: 29622466
133. Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM; **Cancer Genome Atlas Network**, Stuart JM, Benz CC, Laird PW, "Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer," *Cell* 173(2): 291-304 (2018). PMID: 29625048
134. Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang KL, Tokheim C, Cortés-Ciriano I, Jayasinghe R, Chen F, Yu L, Sun S, Olsen C, Kim J, Taylor AM, Cherniack AD, Akbani R, Suphavitai C, Nagarajan N, Stuart JM, Mills GB, Wyczalkowski MA, Vincent BG, Hutter CM, Zenklusen JC, Hoadley KA, Wendl MC, Shmulevich L, Lazar AJ, Wheeler DA, Getz G; **Cancer Genome Atlas Research Network**, "Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics," *Cell* 173(2): 305-320 (2018). PMID: 29625049
135. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M; **Cancer Genome Atlas Research Network**, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N, "Oncogenic Signaling Pathways in The Cancer Genome Atlas," *Cell* 173(2): 321-337 (2018). PMID: 29625050
136. Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwińska P, Mazurek S, Mishra L, Heyn H, Krasnitz A, Godwin AK, Lazar AJ; **Cancer Genome Atlas Research Network**, Stuart JM, Hoadley KA, Laird PW, Noushmehr H, Wiznerowicz M, "Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation," *Cell* 173(2):338-354 (2018). PMID: 29625051
137. Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, Scott AD, Krassowski M, Cherniack AD, Houlihan KE, Jayasinghe R, Wang LB, Zhou DC, Liu D, Cao S, Kim YW, Koire A, McMichael JF, Huchtagowder V, Kim TB, Hahn A, Wang C, McLellan MD, Al-Mulla F, Johnson KJ; **Cancer Genome Atlas Research Network**, Lichtarge O, Boutros PC, Raphael B, Lazar AJ, Zhang W, Wendl MC, Govindan R, Jain S, Wheeler D, Kulkarni S, Dipersio JF, Reimand J, Meric-Bernstam F, Chen K, Shmulevich I, Plon SE, Chen F, Ding L, "Pathogenic Germline Variants in 10,389 Adult Cancers," *Cell* 173(2): 355-370 (2018). PMID: 29625052

138. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Ng PK, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavitai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H; MC3 Working Group; **Cancer Genome Atlas Research Network**, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L, "Comprehensive Characterization of Cancer Driver Genes and Mutations," *Cell* 173(2): 371-385 (2018). PMID: 29625053
139. Chen H, Li C, Peng X, Zhou Z, Weinstein JN; **Cancer Genome Atlas Research Network**, Liang H, "A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples," *Cell* 173(2): 386-399 (2018). PMID: 29625054
140. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V; **Cancer Genome Atlas Research Network**, Hu H, "An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics," *Cell* 173(2): 400-416 (2018). PMID: 29625055
141. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Peadarallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CE; **Cancer Genome Atlas Research Network**, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich L, "The Immune Landscape of Cancer," *Immunity* 48(4): 812-830 (2018). PMID: 29628290
142. Kane JM 3rd, Magliocco A, Zhang Q, Wang D, Klimowicz A, Harris J, **Simko J**, DeLaney T, Kraybill W, Kirsch DG, "Correlation of High-Risk Soft Tissue Sarcoma Biomarker Expression Patterns with Outcome following Neoadjuvant Chemoradiation," *Sarcoma*. 2018 Feb 28;2018:8310950. PMID: 29681762
143. Sirohi D, Vaske C, Sanborn Z, Smith SC, Don MD, Lindsey KG, Federman S, Vankalakunti M, Koo J, Bose S, Peralta-Venturina M, Ziffle JV, Grenert JP, Miller S, Chiu C, Amin MB, **Simko JP**, Stohr BA, Luthringer DJ. " Polyoma virus-associated carcinomas of the urologic tract: a clinicopathologic and molecular study." *Mod Pathol*. 2018 May 15. doi: 10.1038/s41379-018-0065-z. [Epub ahead of print] PMID: 29765141
144. Cooperberg MR, Erho N, Chan JM, Feng FY, Fishbane N, Zhao SG, **Simko JP**, Cowan JE, Lehrer J, Alshalalfa M, Kolisnik T, Chelliserry J, Margrave J, Aranes M, Plessis MD, Buerki C, Tenggara I, Davicioni E, Carroll PR. " The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer." *Eur Urol*. 2018 May 28. pii: S0302-2838(18)30362-2. doi: 10.1016/j.eururo.2018.05.014. [Epub ahead of print] PMID: 29853306
145. Lelo A, Prip F, Harris BT, Solomon D, Berry DL, Chaldeckas K, Kumar A, **Simko J**, Jensen JB, Bhattacharyya P, Mannion C, Kim JS, Philips G, Dyrskjøet L, Waldman T. "STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer." *Clin Cancer Res*. 2018 Jun 28. doi: 10.1158/1078-0432.CCR-17-3244. [Epub ahead of print] PMID: 29954776
146. Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C; **Cancer Genome Atlas Research Network**, Rättsch G,

- "Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients,"
Cancer Cell 34(2): 211-224 (2018). PMID: 30078747
147. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Kwok-Shing Ng P, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H; MC3 Working Group; **Cancer Genome Atlas Research Network**, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L, "Comprehensive Characterization of Cancer Driver Genes and Mutations," Cell 174(4): 1034-1035 (2018). PMID: 30096302
 148. Leapman MS, Nguyen HG, Cowan JE, Xue L, Stohr B, **Simko J**, Cooperberg MR, Carroll PR. "Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy." Eur Urol. 2018 Nov. doi: 10.1016/j.eururo.2018.08.020 PMID: 30181067
 149. Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, **Simko JP**, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. "Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer." JCI Insights. 2018 Sep 6. doi: 10.1172/jci.insight.121497 PMID: 30185663
 150. Hicks RM, **Simko JP**, Westphalen AC, Nguyen HG, Greene KL, Zhang L, Carroll PR, Hope TA. "Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer." Radiology. 2018 Dec; 289(3):730-737. doi: 10.1148/radiol.2018180788 PMID: 3026456
 151. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; **Cancer Genome Atlas Research Network**, Weinstein JN, Mishra L, Akbani R, "A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily," Cell Syst 7(4):422-437 (2018). PMID: 30268436
 152. Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB; **Cancer Genome Atlas Research Network**, Camargo F, Liang H, "Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer," Cell Rep. 2018 Oct 30;25(5):1304-1317.e5. doi: 10.1016/j.celrep.2018.10.001. PMID: 30380420
 153. Behr SC, Aggarwal R, Van Brocklin HF, Flavell RR, Geo K, Small EJ, Blecha J, Jivan S, Hope TA, **Simko JP**, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y. "First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer." J Nucl Med. 2018 Nov 21. pii: jnumed.118.220715. doi: 10.2967/jnumed.118.220715. [Epub ahead of print] PMID: 30464040

154. Greenland NY, Zhang L, Cowan JE, Carroll PR, Stohr BA, **Simko JP**. "Correlation of a Commercial Genomic Risk Classifier with Histologic Patterns in Prostate Cancer." *J Urol*. 2019 Feb 15: 101097JU0000000000000175. doi: 10.1097/JU.0000000000000175. [Epub ahead of print] PMID: 30810466
155. Laguna B, Westphalen AC, Guimarães CT, Whang Z, **Simko J**, Zagoria R. "Uncommon malignant renal tumors and atypical presentation of common ones: a guide for radiologists." *Abdom radiol (NY)*. 2019 Apr; 44(4): 1430-1452 doi: 10.1007/s00261-018-1789-4 PMID: 30311049
156. Friedlander TW, Welty C, Anantharaman A, Schonhoft JD, Jendrisak A, Lee J, Li P, Hough J, Stromlund A, Kobayashi Y, **Simko J**, Farrokhian N, Lindquist K, Greene S, Ontiveros P, Graf R, Rodriguez A, Suraneni M, Wang Y, Landers M, Carroll P, Cooperberg MR, Dittamore R, Paris PL. "Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy for Clinically Localized, High - Risk Prostate Cancer." *J Urol*. 2019 Jun 19:101097JU00000000000000393. doi: 10.1097/JU.00000000000000393. [Epub ahead of print] PMID: 31216253
157. Sirohi D, Devine P, Grenert JP, van Ziffle J, **Simko JP**, Stohr BA. "TP53 structural variants in metastatic prostatic carcinoma." *PLoS One*. 2019 Jun 19;14(6):e0218618. doi: 10.1371/journal.pone.0218618. eCollection 2019. PMID: 31216325
158. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Peadarallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS; **Cancer Genome Atlas Research Network**, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I. The Immune Landscape of Cancer. *Immunity*. 2019 Aug 20;51(2):411-412. doi: 10.1016/j.immuni.2019.08.004. PMID: 31433971
159. Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, **Simko JP**, Chan JM, Lane BR, Davis JW, Davicioni E, Feng FY, McCue P, Kim H, Den RB, Bismar TA, Carroll PR, Cooperberg MR. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. *Prostate Cancer Prostatic Dis*. 2019 Aug 27. doi: 10.1038/s41391-019-0167-9. [Epub ahead of print] PMID: 31455846
160. Belkora J, Chan JM, Cooperberg MR, Neuhaus J, Stupar L, Weinberg T, Broering JM, Tenggara I, Cowan JE, Rosenfeld S, Kenfield SA, Van Blarigan EL, **Simko JP**, Witte J, Carroll PR, "Development and pilot evaluation of a personalized decision support intervention for low risk prostate cancer patients," *Cancer Med*. 2019 Nov 12. doi: 10.1002/cam4.2685. [Epub ahead of print] PMID: 31714037
161. Greenland NY, Cowan JE, Zhang L, Carroll PR, Chan E, Stohr BA, Simko JP, "Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4" *Prostate* 80(8): 653-659 (2020). PMID: 32220141
162. van Leenders GJLH, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, Litjens G, McKenney JK, Melamed J, Mottet N, Paner GP, Samaratinga H, Schoots IG, Simko JP, Tsuzuki T, Varma M, Warren AY, Wheeler TM, Williamson SR, Iczkowski KA; ISUP

Grading Workshop Panel Members, "The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma," *Am J Surg Pathol.* 2020 May 26. Online ahead of print. PMID: 32459716

163. Cario CL, Chen E, Leong L, Emami NC, Lopez K, Tenggara I, Simko JP, Friedlander TW, Li PS, Paris PL, Carroll PR, Witte JS, "A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer," *BMC Cancer*20(1):820 (2020). PMID: 32859160

164. Fendler WP, Calais J, Eiber M, Simko JP, Kurhanewicz J, Santos RD, Feng FY, Reiter RE, Rettig MB, Nickols NG, Kishan AU; PSMA PET Reader Group, Slavik R, Carroll PR, Lawhn-Heath C, Herrmann K, Czernin J, Hope TA, "False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial," *Eur J Nucl Med Mol Imaging.* 2020 Aug 17. Online ahead of print. PMID: 32808077

NON-PEER REVIEWED PUBLICATIONS

1. S.J. DeArmond, **J.P. Simko** and D.A. Gaskin, "The Molecular and Genetic Basis of Neurodegenerative Diseases," in **Modern Surgical Pathology**, N. Weidner, Ed. (W.B. Saunders, New York, 2003) pp. 2121-2153.
2. **JP Simko** and FM Waldman, "Molecular and Special Techniques," in **Immunomicroscopy: A Diagnostic Tool for the Surgical Pathologist, 3rd Edition**, C. Taylor, R. Cote Eds. (Elsevier, St. Louis, 2006).
3. **JP Simko**, Editorial for H. Eyas, et al., "Tertiary Gleason Pattern 5 is a Powerful Predictor of Biochemical Relapse in Patients with Gleason Score 7 Prostatic Adenocarcinoma," *J. Urol.* (2006).
4. BM Ljung and **JP Simko**, "Issues and Methodologies for Sampling Breast Cancers for Molecular Studies and Diagnosis: Lessons from a Pathologist's Bench," in **Seminars in Breast Disease**, A. Thor Ed. (Elsevier, St. Louis, 2007).
5. S.J. DeArmond, TA Tousseyn, **J.P. Simko** and D.A. Gaskin, "The Molecular and Genetic Basis of Neurodegenerative Diseases" in **Modern Surgical Pathology Second Edition**, N. Weidner, Ed. (W.B. Saunders, New York, 2009) pp. 2039-2068.
6. **Simko JP**, "Letter to the editor," *J Urol* 190(6): 2066-7 (2013).